2. Academic Validation
  3. Drugs in development for herpes simplex and varicella zoster virus

Drugs in development for herpes simplex and varicella zoster virus

  • Clin Pharmacol Ther. 2017 Jul;102(1):30-32. doi: 10.1002/cpt.647.
A Birkmann 1,  H Zimmermann 1
Affiliations

Affiliation

  • 1 AiCuris Anti-infective Cures GmbH, Wuppertal, Germany.
PMID: 28160282 DOI: 10.1002/cpt.647
Abstract

The alpha-herpesviruses varicella zoster virus (VZV) and herpes simplex virus (HSV) share common features including lifelong persistence in sensory ganglia and the risk of recurrences. For both HSV and VZV, standard-of-care (SoC) is based on nucleoside analogs (NAs), which require specific activation in infected cells. These existing drugs exhibit substantial limitations, warranting the development of new and more effective drugs.

Figures
Products